Category: Press Mabwell Receives IND Clearance from FDA for Initiating Clinical Trials for its Anti-CD47/PD-L1 Bispecific Antibody Read More NMPA Accepted IND Application of China’s First Anti-Nectin-4 ADC Drug NMPA Accepted IND Application of China's First Anti-Nectin-4 ADC Drug Read More First China-made Anti-ST2 Antibody Developed by Mabwell Approved for Clinical Study Read More Mabwell participated in the Shanghai Biopharmaceutical Industry Innovation Alliance as the Secretary-General Read More Mabwell Closes Series A Financing of 1.97 Billion Yuan to Speed Up New Variety R&D and Industrialization Read More